GD4 POTENTIAL HOSPITAL SAVINGS RELATED TO THE ADMINISTRATION OF ESOMEPRAZOLE TABLETS THROUGH GASTRIC TUBES IN PATIENTS CURRENTLY TREATED WITH INJECTABLE PPIS  by Duru, G et al.
614 Abstracts
Dutch guidelines for pharmacoeconomic research.
DALYs were calculated using data on number of deaths
due to gastroenteritis and age at death from Statistics
Netherlands. Disability weights for both mild and severe
cases of gastroenteritis were taken from a Dutch national
study on the burden of diseases. RESULTS: Of the 4860
participants in the cohort, 1052 case episodes were
observed. Of these cases, 774 (74%) participated in the
case-control component. Of these, 646 (83%) completed
data collection. The overall standardised incidence of 
gastroenteritis was 283 per 1000 person-years, with an
estimated total of 4.5 million cases per year. Total costs
per case were €68.80, with productivity losses (€55.50)
being the major cost driver. Total cost to society were esti-
mated at €308 million in 1999 (95% CI €221–393
million). Gastroenteritis was associated with a loss of
67,000 DALYs. CONCLUSIONS: Although costs and
disease burden are low for individual cases, gastroenteri-
tis is associated with a high disease burden and con-
siderable costs to society due to a high incidence in the
population.
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OBJECTIVES: Intravenous Proton Pump Inhibitors
(PPIs) are widely used in hospital. The galenic formula-
tion of esomeprazole tablets (Multi Unit Pellet System)
enables water dispersion and subsequent administration
through a gastric tube (GT), thus offering an alternative
to injectable PPIs. The primary objective of this study was
to estimate the percentage of hospital patients treated
with intravenous PPIs that are potential candidates to a
treatment with esomeprazole tablets administered via a
GT. Secondary objectives were to derive the subsequent
savings in terms of drug acquisition cost and nurses time
saving. METHODS: Hospitals, stratiﬁed on their admin-
istrative status, were randomly selected. In each hospital,
departments consuming more than 80% of the total
injectable PPIs were identiﬁed. Patient data collection
(including presence of a GT) was done during one single
day. The time to administrate injectable PPI and
esomeprazole tablets through a GT was estimated by
nurses; drug cost calculations were done with undis-
counted prices including taxes. RESULTS: A database
including 179 patients in 19 different hospital centres was
collected. Mean age (SD) was 61.9 (16.3) years and
53.9% of patients were male. Patients were hospitalised
for 13.1 (16.5) days in surgery department (41%),
medical department (37.1%), intensive care unit (21.9%).
A total of 46.6% of patients were hospitalised for cancers
and 30.1% for digestive diseases. Total number of
patients which had GT was 33.3%. Median nurse times
to administrate injectable PPI and esomeprazole tablets
through a GT were respectively 5 and 3 minutes (-40%),
while the drug costs were respectively €8.08 and €1.49 
(-82%). CONCLUSIONS: This study shows that 33%
of patients treated with injectable PPI have a gastric tube.
These patients are potential candidates to be treated with
esomeprazole tablet through a gastric tube with signiﬁ-
cant beneﬁts both in terms of drug acquisition cost and
nurse time saving.
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The PROGRESS trial demonstrated the effectiveness of
perindopril/indapamide in secondary stroke prevention
(SSP). No existing economic study has incorporated these
ﬁndings in a cost-beneﬁt analysis. OBJECTIVES: The
objective of this analysis was to evaluate the cost/beneﬁt
of perindopril/indapamide in SSP. METHODS: The
model used a decision tree approach to estimate direct
cost savings associated with SSP for a hypothetical cohort
of 10,000 ﬁrst stroke survivors from an HMO’s perspec-
tive (1 Mio covered lives) over a 3-year time period. Inci-
dence estimates for 2nd stroke and Health care utilization
as well as pharmacoeconomic estimates are presented 
for each year and separated for the two major stroke
types (ischaemic and hemorrhagic stroke). First, stroke
incidence and transition probabilities for Health care 
utilization were ed from the published epidemiologic 
literature, incidence of second strokes from the
PROGRESS trial. Cost for stroke-related hospitalization
and re-hospitalization, rehabilitation, nursing home, and
ambulatory care derived from national data and pub-
lished literature. Historical cost data was inﬂation-
adjusted to 2001 values, savings in the 2nd and 3rd year
were discounted at 3%, and health care CPI inﬂation-
adjusted at 4.7%. Treatment and control group (no SSP
medication) were replenished after the 1st and 2nd year
in equal numbers with newly SSP eligible patients (new
ﬁrst stroke survivors of the HMO population). Drug
prices were deﬁned as WAC-20% plus $5 co-pay. Sensi-
tivity analysis on stroke incidences, selected transition
probabilities and costs will be presented. RESULTS: SSP
with perindopril/indapamide saved 28 lives and 110
strokes in the ﬁrst year (after 3 years 169 and 325 respec-
tively). Treatment achieved a net beneﬁt of $803,000 in
the ﬁrst, $3,267,253 in the second and $6,207,814 by the
third year. The cost per stroke prevented was $24,648 and
$47,412 per death averted over the 3 year period. 
